New Strong Sell Stocks for September 21st

Zacks added AGCO, Aegon and Boston Scientific to its Rank #5 (Strong Sell) list after current-year consensus EPS estimates were cut over the past 60 days. Estimates fell 10.1% for Aegon, 9.3% for AGCO and 2.1% for Boston Scientific, signaling deteriorating near-term earnings expectations. The revisions are a negative stock-specific catalyst but are unlikely to have broad market impact.

Analysis

This is a low-information signal rather than a standalone catalyst: estimate-revision screens often lag company guidance, sell-side model resets, and macro data already reflected in prices. The actionable distinction is dispersion in underlying earnings quality. AGCO's downgrade is more consequential because farm-equipment demand is late-cycle and operating leverage is high; incremental dealer inventory reductions can drive a sharper-than-expected margin de-rate versus Deere (DE), while CNH Industrial (CNH) offers the cleaner relative short if its North American replacement-demand assumptions remain elevated.

AEG's revisions should be evaluated through solvency and capital-return sensitivity rather than headline EPS. A weaker euro/dollar translation, lower variable investment income, or adverse mortality assumptions can reduce reported earnings without impairing distributable capital, making an outright short unattractive unless its dividend/buyback capacity or Solvency II ratio weakens. For BSX, a modest estimate reset is insufficient to challenge the structural premium attached to procedure growth and new-product execution; short interest based solely on a rankings change risks a squeeze at the next revenue-growth print.

Over the next few days, expect little durable price discovery absent incremental guidance or consensus revisions from multiple analysts. Over 1-3 months, AGCO dealer-inventory commentary and DE/CNH order-book trends are the key read-through; over 6-18 months, lower farm income and financing affordability could extend a replacement-cycle downturn. The contrarian view is that AGCO may already discount much of the earnings trough if inventories normalize faster than feared, while BSX's estimate change may create a tactical entry only if organic-growth guidance remains intact.

Key Decisions for Investors

• Do not initiate broad shorts in AEG or BSX on this screen alone; require a company guidance cut, at least 5% further FY consensus EPS decline, or a sector-relative break before acting.
• Establish a 1-3 month relative-value watch: short AGCO versus long DE only if AGCO dealer inventories rise or FY margin expectations fall further while DE maintains precision-ag and service revenue guidance. Target 8-12% relative downside with a 4-5% stop on a reversal in farm-income or order commentary.
• If seeking a more cyclical bearish expression, monitor short CNH versus long DE around upcoming dealer/order updates; the thesis is invalidated if CNH demonstrates improving North American retail demand and sustains price realization.
• Treat BSX weakness as a buy-watch rather than a short: consider a tactical long only after confirmation that procedure growth and full-year organic revenue guidance are maintained. A guidance reduction or slowing electrophysiology/endoscopy growth would invalidate the setup.
• For AEG, monitor the next solvency ratio, buyback/dividend announcement, and euro translation effects. A maintained or expanding capital-return program would argue that the earnings revision is accounting noise rather than a reason to reduce exposure.